Short answers, pulled from the story.
Prostate cancer begins as uncontrolled growth of cells within the prostate gland, a small organ situated below the bladder in the male reproductive system. Most tumors originate in the peripheral zone, which is the outermost layer of this gland.
Blood tests measure levels of prostate-specific antigen or PSA to screen for the disease before symptoms appear. Men with PSA above 4ng/mL face increased risk, while those exceeding 10ng/mL have even higher odds as more than half develop the disease.
Men diagnosed with low-risk tumors often defer treatment and monitor progression through active surveillance programs involving testing every six months. When therapy becomes necessary, options include radiation or surgical removal of the entire gland known as radical prostatectomy.
Metastatic disease requires androgen deprivation therapy reducing male sex hormones that prostate cells need to survive. First-line drugs like leuprolide or goserelin block testosterone synthesis but cause brief initial rises potentially worsening symptoms before improvement occurs.
A prostate mass was first described in 1817 by English surgeon George Langstaff following autopsy of a man dying at 68 with urinary symptoms. John Adams provided the first confirmed cancer case in 1853 when he had pathologists examine a tumor from a patient suffering similar problems.